account_id none on file
legal_name Pasithea Therapeutics Corp.
ticker KTTA
cik 1841330
domain pasithea.com
linkedin_company_url https://www.linkedin.com/company/75885048
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 12 executives 4 family 0
why_nownone on file
callsnone on file
filings
The Company’s previous leases were related to office space. The Company determines whether a contract is or contains a lease at the time of the contract’s inception based on the presence of identified assets and the Company’s right to obtain substantially all the economic benefit from or to direct the use of such assets.
filing / Aug 14, 2026 / receipt
The Company’s previous leases were related to office space. The Company determines whether a contract is or contains a lease at the time of the contract’s inception based on the presence of identified assets and the Company’s right to obtain substantially all the economic benefit from or to direct the use of such assets.
filing / Aug 14, 2026 / receipt
Schneiderman’ employment agreement, he holds the position of Chief Financial Officer and currently receives a base salary of $456,000 annually (effective January 1, 2026).
filing / Aug 7, 2026 / receipt
was hired as Chief Financial Officer of the Company on October 11, 2022. Total compensation for 2025 for Mr. Schneiderman includes
filing / Aug 7, 2026 / receipt
method is referred to as “householding” and can result in significant cost savings. To take advantage of this opportunity,
filing / Aug 7, 2026 / receipt
Daniel Schneiderman 48 Chief Financial Officer
filing / Aug 7, 2026 / receipt
Simon Dumesnil (1)(2)(3) 49 Director
filing / Aug 7, 2026 / receipt
Alfred Novak (1)(2)(3) 78 Director
filing / Aug 7, 2026 / receipt
Dr. Emer Leahy has served on our Board since June 2021.
filing / Aug 7, 2026 / receipt
Schneiderman’ employment agreement, he holds the position of Chief Financial Officer and currently receives a base salary of $456,000 annually (effective January 1, 2026).
filing / Aug 7, 2026 / receipt
was hired as Chief Financial Officer of the Company on October 11, 2022. Total compensation for 2025 for Mr. Schneiderman includes
filing / Aug 7, 2026 / receipt
method is referred to as “householding” and can result in significant cost savings. To take advantage of this opportunity,
filing / Aug 7, 2026 / receipt
executives
| Alfred Novak | Director | - | receipt |
| Daniel Schneiderman | Chief Financial Officer | receipt | |
| Emer Leahy | Director | - | receipt |
| Simon Dumesnil | Director | - | receipt |
familynone on file
upcoming
| 2026-11-12 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug pasithea-therapeutics-corp
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$